Fibrocystic Breasts Diagnostics and Treatment Market Research Report – Forecast to 2027

Global Fibrocystic Breasts Diagnostics and Treatment Market: Type (Diagnosis- Mammogram and Breast Biopsy, Treatment- Medications, Fine-Needle Aspiration, Surgical Excision, Oral Contraceptives), End-Users (Hospitals and Others)–Global Forecast Till 2027

ID: MRFR/Pharma/4987-HCR | | Region: Global | 100 pages

Market Scenario


The global fibrocystic breasts diagnostics and treatment market is expected to register a significant growth during the forecast period (2018–2023).


The fibrocystic breast disease, also known as fibrocystic change or fibrocystic breasts, is a non-cancerous condition in which the breasts feel lumpy. The breast lumps are due to fibrocystic changes. These lumps are formed due to the collection of fibrous tissue at an area of the breast. The ligaments and scar tissues are made up of fibrous tissue. the changes in breast tissue due to the fluctuating hormone levels made by the ovaries results in the occurrence of fibrocystic breasts. The changes seem to be troublesome and result in breast swelling and painful breast lumps. It mainly affects women between their 30s and 50s and lingers through their perimenopause and menopause. Presence of fibrocystic breast disease increases the risk of breast cancer.


Increase in incidences of breast cancer; especially among women above the age of 35 during menopause (are more susceptible to breast cancer), and growth in awareness regarding breast cancer screening programs drive the market growth. Additionally, the emergence of technologically advanced and minimally invasive breast biopsy devices is expected to provide lucrative opportunities in the untapped market.  However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Moreover, restrains for the market includes the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the global fibrocystic breasts diagnostics and treatment negatively. 


Segmentation


The global fibrocystic breasts diagnostics and treatment market has been segmented into type and end users.


On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis is segmented into mammogram and breast biopsy. The treatment is segmented into medications, fine-needle aspiration, surgical excision, oral contraceptives. The medications are further segmented into acetaminophen, nonsteroidal anti-inflammatory drugs.


On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, rehab centers, research institutes, and others.


On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.


The European fibrocystic breasts diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The fibrocystic breasts diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The fibrocystic breasts diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Fibrocystic Breasts Diagnostics and Treatment Market Share, by Region, 2017 (%)


Fibrocystic Breasts Diagnostics and Treatment Market Share


Source: MRFR Analysis


In the fibrocystic breast diagnostics and treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into cancer diagnostic. More than half of women experience fibrocystic breast changes at some point in their lives. According to the American Cancer Society's evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.


The European market is expected to hold the second largest market share. The market growth in this region can be attributed to increasing amount of alcohol consumption by women, changes in estrogen levels due to increase in intake of birth control pills and increasing use of hormone replacement therapy (HRT) are boosting the European market.


Whereas the market share in Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increasing government initiatives and rising healthcare expenditure.


The market in the Middle East & Africa is expected to account for the smallest share of the global fibrocystic breast diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the global fibrocystic breast diagnostics and treatment market are Argon Medical Devices, Boston Scientific, CareFusion Corporation (Acquired by Becton, Dickinson and Company), C. R. Bard, Inc, Cook Medical, Devicor Medical Products Inc., Gallini Medical Devices, Hologic, Inc., INRAD, Inc., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd, Bayer AG, Allergan plc.


Global Fibrocystic Breast Diagnostics and Treatment Market, by Type



  • Diagnosis

  • Mammogram

  • Breast biopsy

  • Treatment

  • Medications

  • Acetaminophen

  • Nonsteroidal anti-inflammatory drugs

  • Fine-needle aspiration

  • Surgical excision

  • Oral contraceptives


Global Fibrocystic Breast Diagnostics and Treatment Market, by End-Users



  • Hospitals

  • Clinics

  • Diagnostic centers

  • Specialty Clinics and Rehab Centers

  • Research Institutes

  • Others


Global Fibrocystic Breast Diagnostics and Treatment Market, by Region


Americas


  • North America

  • US

  • Canada

  • South America


Europe


  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific


  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific


Middle East & Africa


  • Middle East

  • Africa


 Intended Audience



  • Governmental Agency

  • Educational Organizations

  • Medical Device Manufacturers

  • Research Institutes and Academic Centers

  • Market Research and Consulting



Frequently Asked Questions (FAQ) :


The restraints are the high cost of the procedure and risk associated with it.

End users included in the report are clinics, hospitals, specialty clinics, diagnostic centers, research institutes, rehab centers, and others.

North America would control the better fibrocystic breast diagnostics and treatment market.

The players involved are CareFusion Corporation (Acquired by Becton, Dickinson, and Company), Argon Medical Devices, Boston Scientific, Cook Medical, C. R. Bard, Inc, Hologic, Inc., Devicor Medical Products Inc., Gallini Medical Devices, Merck & Co., Inc., INRAD, Inc., Teva Pharmaceutical Industries Ltd, Bayer AG, Pfizer Inc., Allergan plc., and others.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Fibrocystic Breast Diagnostics and Treatment Market, by Type

6.1 Introduction

6.2 Diagnosis

6.2.1 Mammogram

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.2.2 Breast biopsy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Treatment

6.3.1 Medications

6.3.1.1 Acetaminophen

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.1.2 Nonsteroidal anti-inflammatory drugs

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.2 Fine-needle aspiration

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.3 Surgical excision

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3.4 Oral contraceptives

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Fibrocystic Breast Diagnostics and Treatment Market, by End-Users

7.1 Introduction

7.2 Hospitals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Ambulatory Surgery Centers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Fibrocystic Breast Diagnostics and Treatment Market, by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 US

8.2.1.2 Canada

8.2.2 South America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 UK

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia-Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest of Asia-Pacific

8.5 Middle East & Africa

8.5.1 Middle East

8.5.2 Africa

Chapter 9. Company Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Development & Strategies

Chapter 10. Company Profiles

10.1 Argon Medical Devices

10.1.1 Company Overview

10.1.2 Type Overview

10.1.3 Financials Overview

10.1.4 Key Developments

10.1.5 SWOT Analysis

10.2 Boston Scientific

10.2.1 Company Overview

10.2.2 Type Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 CareFusion Corporation (Acquired by Becton, Dickinson and Company)

10.3.1 Company Overview

10.3.2 Type Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 C. R. Bard, Inc.

10.4.1 Company Overview

10.4.2 Technology/Business Segment Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 Cook Medical

10.5.1 Company Overview

10.5.2 Type Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.6 Devicor Medical Products Inc.

10.6.1 Company Overview

10.6.2 Type Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.7 Gallini Medical Devices

10.7.1 Overview

10.7.2 Type Overview

10.7.3 Financial Overview

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Hologic, Inc.

10.8.1 Overview

10.8.2 Type/ Technology Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.7 INRAD, Inc.

10.7.1 Overview

10.7.2 Type Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Merck & Co., Inc.

10.8.1 Overview

10.8.2 Type Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.10 Pfizer Inc.

10.10.1 Overview

10.10.2 Type Overview

10.10.3 Financials

10.10.4 Key Developments

10.10.5 SWOT Analysis

10.10 Teva Pharmaceutical Industries Ltd

10.10.1 Overview

10.10.2 Type Overview

10.10.3 Financials

10.10.4 Key Developments

10.10.5 SWOT Analysis

10.13 Bayer AG

10.13.1 Overview

10.13.2 Type Overview

10.13.3 Financials

10.13.4 Key Developments

10.13.5 SWOT Analysis

10.14 Allergan plc.

10.14.1 Overview

10.14.2 Type Overview

10.14.3 Financials

10.14.4 Key Developments

10.14.5 SWOT Analysis

Chapter 11 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s Viewpoint

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Predictions for the Fibrocystic Breast Diagnostics and Treatment Industry

Chapter 12. Appendix

LIST OF TABLES

Table 1 Global Fibrocystic Breast Diagnostics and Treatment Market Synopsis, 2020–2027

Table 2 Global Fibrocystic Breast Diagnostics and Treatment Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Fibrocystic Breast Diagnostics and Treatment Market, by Region, 2020–2027 (USD Million)

Table 4 Global Fibrocystic Breast Diagnostics and Treatment Market, by Type, 2020–2027 (USD Million)

Table 5 Global Fibrocystic Breast Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Table 6 North America: Fibrocystic Breast Diagnostics and Treatment, by Type, 2020–2027 (USD

Million)

Table 7 North America: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2020–2027 (USD Million)

Table 8 US: Fibrocystic Breast Diagnostics and Treatment, by Type, 2020–2027 (USD Million)

Table 9 US: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2020–2027 (USD Million)

Table 10 Canada: Fibrocystic Breast Diagnostics and Treatment, by Type, 2020–2027 (USD Million)

Table 11 Canada: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2020–2027 (USD Million)

Table 12 South America: Fibrocystic Breast Diagnostics and Treatment, by Type, 2020–2027 (USD

Million)

Table 13 South America: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2020–2027 (USD Million)

Table 14 Europe: Fibrocystic Breast Diagnostics and Treatment, by Type, 2020–2027 (USD Million)

Table 15 Europe: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2020–2027 (USD Million)

Table 16 Western Europe: Absorbable Surgical Sutures, by Type, 2020–2027 (USD

Million)

Table 17 Western Europe: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2020–2027 (USD Million)

Table 18 Eastern Europe: Fibrocystic Breast Diagnostics and Treatment, by Type, 2020–2027 (USD

Million)

Table 19 Eastern Europe: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2020–2027 (USD Million)

Table 20 Asia-Pacific: Fibrocystic Breast Diagnostics and Treatment, by Type, 2020–2027 (USD

Million)

Table 21 Asia-Pacific: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2020–2027 (USD Million)

Table 22 Middle East & Africa: Fibrocystic Breast Diagnostics and Treatment, by Type, 2020–2027

(USD Million)

Table 23 Middle East & Africa: Fibrocystic Breast Diagnostics and Treatment, by End-users, 2020–2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Fibrocystic Breast Diagnostics and Treatment Market

Figure 3 Market Dynamics for

the Global Fibrocystic Breast Diagnostics and Treatment Market

Global Fibrocystic Breast Diagnostics and Treatment Market

Figure 4 Global Fibrocystic Breast Diagnostics and Treatment Market Share, by Type, 2020

Figure 5 Global Fibrocystic Breast Diagnostics and Treatment Market, by End-users, 2020–2027 (USD Million)

Figure 6 Global Fibrocystic Breast Diagnostics and Treatment Market Share, by Region, 2020

Figure 7 North America: Fibrocystic Breast Diagnostics and Treatment Share, by Country, 2020

Figure 8 Europe: Fibrocystic Breast Diagnostics and Treatment Share, by Country, 2020

Figure 9 Asia-Pacific: Fibrocystic Breast Diagnostics and Treatment Share, by Country, 2020

Figure 10 Middle East & Africa: Fibrocystic Breast Diagnostics and Treatment Share, by Country, 2020

Figure 11 Global Fibrocystic Breast Diagnostics and Treatment Market: Company Share Analysis, 2020 (%)

Figure 12 Argon Medical Devices: Key Financials

Figure 13 Argon Medical Devices: Segmental Revenue

Figure 14 Argon Medical Devices: Geographical Revenue

Figure 15 Boston Scientific: Key Financials

Figure 16 Boston Scientific: Segmental Revenue

Figure 17 B Boston Scientific: Geographical Revenue

Figure 18 CareFusion Corporation (Acquired by Becton, Dickinson and Company): Key Financials

Figure 19 CareFusion Corporation (Acquired by Becton, Dickinson and Company): Segmental Revenue

Figure 20 CareFusion Corporation (Acquired by Becton, Dickinson and Company): Geographical Revenue

Figure 21 C. R. Bard, Inc.: Key Financials

Figure 22 C. R. Bard, Inc: Segmental Revenue

Figure 23 C. R. Bard, Inc.: Geographical Revenue

Figure 24 Cook Medical: Key Financials

Figure 25 Cook Medical: Segmental Revenue

Figure 26 Cook Medical: Geographical Revenue

Figure 27 Devicor Medical Products Inc.: Key Financials

Figure 28 Devicor Medical Products Inc.: Segmental Revenue

Figure 29 Devicor Medical Products Inc.: Geographical Revenue

Figure 30 Gallini Medical Devices: Key Financials

Figure 31 Gallini Medical Devices: Segmental Revenue

Figure 32 Gallini Medical Devices: Geographical Revenue

Figure 33 Hologic, Inc.: Key Financials

Figure 34 Hologic, Inc.: Segmental Revenue

Figure 35 Hologic, Inc.: Geographical Revenue

Figure 36 INRAD, Inc.: Key Financials

Figure 37 INRAD, Inc.: Segmental Revenue

Figure 38 INRAD, Inc.: Geographical Revenue

Figure 39 Merck & Co., Inc.: Key Financials

Figure 40 Merck & Co., Inc.: Segmental Revenue

Figure 41 Merck & Co., Inc.: Geographical Revenue

Figure 42 Pfizer Inc.: Key Financials

Figure 43 Pfizer Inc.: Segmental Revenue

Figure 44 Pfizer Inc.: Geographical Revenue

Figure 45 Teva Pharmaceutical Industries Ltd: Key Financials

Figure 46 Teva Pharmaceutical Industries Ltd: Segmental Revenue

Figure 47 Teva Pharmaceutical Industries Ltd: Geographical Revenue

Figure 48 Bayer AG: Key Financials

Figure 49 Bayer AG: Segmental Revenue

Figure 50 Bayer AG: Geographical Revenue

Figure 51 Allergan plc.: Key Financials

Figure 52 Allergan plc.: Segmental Revenue

Figure 53 Allergan plc.: Geographical Revenue